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RESEARCH ARTICLE Open Access
The effects of CEP-37440, an inhibitor of
focal adhesion kinase, in vitro and in vivo
on inflammatory breast cancer cells
Israa Salem1, Manal Alsalahi1, Inna Chervoneva2, Lucy D. Aburto1, Sankar Addya3, Gregory R. Ott4,
Bruce A. Ruggeri4,6, Massimo Cristofanilli1,5 and Sandra V. Fernandez1*
Abstract
Background: Inflammatory breast cancer (IBC) is an aggressive type of advanced breast cancer with a poor prognosis.
We recently found that focal adhesion kinase 1 (FAK1) is upregulated and phosphorylated (active) in IBC. In this study,
we investigated the effect of CEP-37440, a dual inhibitor of FAK1 and anaplastic lymphoma kinase (ALK), using human
IBC cell lines and preclinical models of IBC.
Methods: Cell proliferation assays were performed in the presence of several concentrations of CEP-37440 using IBC
and triple-negative breast cancer non-IBC cell lines. In vitro, we studied the expression of total FAK1, phospho-FAK1
(Tyr 397), total ALK and phospho-ALK (Tyr 1604). In vivo, we tested CEP-37440 using FC-IBC02, SUM149, and SUM190
IBC xenograft mouse models.
Results: CEP-37440 at low concentration decreased the proliferation of the IBC cell lines FC-IBC02, SUM190, and KPL4,
while not affecting the proliferation of normal breast epithelial cells. At higher concentration, CEP-37440 was also able
to inhibit the proliferation of the IBC cell line MDA-IBC03 and the triple-negative non-IBC cell lines MDA-MB-231 and
MDA-MB-468; the IBC cell line SUM149 showed a slight response to the drug. CEP-37440 decreased the cell proliferation
of FC-IBC02, SUM190, and KPL4 by blocking the autophosphorylation kinase activity of FAK1 (Tyr 397). None of the cells
evaluated expressed ALK. In vivo, after 7 weeks of CEP-37440 treatment, the SUM190, FC-IBC02, and SUM149 breast
tumor xenografts were smaller in mice treated with 55 mg/kg bid CEP-37440 compared to the controls; the tumor
growth inhibition (TGI) was 79.7 %, 33 %, and 23 %, respectively. None of the FC-IBC02 breast xenografts mice treated
with CEP-37440 developed brain metastasis while 20 % of the mice in the control group developed brain metastasis.
Expression array analyses in FC-IBC02 cells showed that CEP-37440 affects the expression of genes related to apoptosis,
interferon signaling, and cytokines.
Conclusions: CEP-37440 is effective against some IBC cells that express phospho-FAK1 (Tyr 397), and its antiproliferative
activity is related to its ability to decrease phospho-FAK1. Our results suggest that combinational therapies could be
more effective than using CEP-37440 as a single agent.
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Background
Inflammatory breast cancer (IBC) is a very aggressive type
of advanced breast cancer with a poor prognosis. IBC oc-
curs typically in patients under the age of 50 and is often
misdiagnosed as an infection since it does not present as a
lump [1]. The clinical symptoms of IBC involve the rapid
onset of changes in the skin overlying the breast, including
edema, redness, and swelling exhibiting a wrinkled, orange
peel-like appearance of the skin known as peau d’orange
[2]. This peculiar presentation is associated with the inva-
sion of aggregates of tumor cells, defined as tumor emboli,
into the dermal lymphatics, where they obstruct the
lymph channels [3, 4]. Although IBC currently accounts
for only 2–6 % of all breast cancer cases in the United
States and up to 20 % of all breast cancers globally [1, 5–
7], its incidence is dramatically increasing [2, 4]. Further-
more, due to its propensity to rapidly metastasize, IBC is
responsible for a disproportionate number (15 %) of breast
cancer-related deaths [7–9]. IBC is either stage III or IV
disease, depending on whether cancer cells have spread
only to nearby lymph nodes or to other tissues as well. At
the time of diagnosis, most IBC patients have lymph node
metastases, and approximately 30 % have distant metasta-
ses in brain, bones, visceral organs, and soft tissue [1].
Currently, there is no adequate adjuvant therapy to reduce
the risk of recurrence and mortality in IBC patients.
We recently found that focal adhesion kinase 1 (FAK1
or PTK2) is amplified, upregulated and phosphorylated
(active) in IBC [10]. FAK1 is a nonreceptor tyrosine kinase
that localizes to areas termed focal adhesions where the cell
membrane attaches to the extracellular matrix. FAK1 acti-
vation relies upon autophosphorylation of the Tyr 397 site
that is found in the N-terminal domain; FAK1 Tyr 397
binds various signaling proteins, including Src, PI-3 kinase,
and Grb-7. FAK1 also binds epidermal growth factor
receptor (EGFR), vascular epidermal growth factor re-
ceptor (VEGFR), p53, and other molecules that are crit-
ical for tumor growth and progression [11]. It controls
various cellular pathways, including proliferation, via-
bility, and survival, and its overexpression has been
linked to anoikis resistance [12–15]. The activation and
phosphorylation of FAK1 stimulated by many forms of
oncogenic transformation provide a plausible mechan-
ism for the anchorage-independent growth of cancer
cells. FAK1 overexpression correlates negatively with
patient outcome and is associated with increased cell
migration, invasion, and metastasis; elevated FAK1 ex-
pression has been reported in multiple human epithelial
tumors [14, 16–20].
CEP-37440 is a potent ATP-competitive, highly kinase
selective, and orally active inhibitor of FAK1 (enzymatic
IC50: 2.3 nM, cellular IC50: 88 nM) and anaplastic
lymphoma kinase (ALK) (enzymatic IC50: 3.5 nM, cellu-
lar IC50: 40 nM, cellular IC50 in 75 % human plasma: 120
nM) [21]. In addition to a favorable metabolic stability and
pharmacokinetic profile preclinically, CEP-37440 is also a
brain penetrant [21]. In this study, we investigated the ef-
fect of CEP-37440 using human IBC cells and preclinical
models of IBC. We found that CEP-37440 was able to in-
hibit the proliferation of certain IBC cells by decreasing
the levels of phospho-FAK1 (Tyr 397); none of the cells
expressed ALK. Studies using IBC xenograft models
showed that CEP-37440 also effectively reduces the
growth of the primary tumor xenografts and inhibits
the development of brain metastases in mice.
Methods
Cell lines
The cell lines used are described in Table 1. The SUM149
and SUM190 cell lines were purchased from Asterand Inc.
Table 1 Sensitivity of the cell lines to CEP-37440
Cell line Type Subtype GI50 (nM) Reference
ESR PgR ErbB2
FC-IBC02 IBC Neg Neg Neg 91 [10]
KPL4 IBC Neg Neg Post ~900 [41]
SUM190 IBC Neg Neg Post 890 [42]
MDA-IBC03 IBC Neg Neg Post 1860 [43]
SUM149 IBC Neg Neg Neg >3000 [42]
MCF-12A Normal-like breast epithelial cells Neg Neg Neg 1516 [44]
MCA-10A Normal-like breast epithelial cells Neg Neg Neg 1700 [45]
MDA-MB-231 BC (non-IBC) Neg Neg Neg 1930 [46]
MDA-MB-468 BC (non-IBC) Neg Neg Neg 1275 [46]
Inflammatory breast cancer (IBC), breast cancer (BC) non-IBC, and normal-like breast epithelial cell lines were grown in the presence of different concentrations of
CEP-37440 (cell proliferation assays). The GI50 indicate the CEP-37440 concentration required to reduce growth rates to 50 % of the maximum rate. The GI50 was
calculated for each cell line at t = 144 h of CEP-37440 treatment using sigmoidal dose response curve (variable slope) in GraphPad Prism (GraphPad Software Inc.,
La Jolla, CA, USA)
ESR estrogen receptor, PgR progesterone receptor, ErbB2 epidermal growth factor receptor 2
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(Detroit, MI, USA). The MDA-IBC03 cells were obtained
from W.A. Woodward, and KPL4 cells were obtained from
N.T. Ueno, The University of Texas MD Anderson Cancer
Center, TX, USA. All other cell lines, MDA-MB-231,
MDA-MB-468, MCF-10A, and MCF-12A, were purchased
from American Type Culture Collection (ATCC; Manassas,
VA, USA). The new model of IBC, designated as FC-
IBC02, was previously developed in our laboratory, through
the isolation of tumor cells from the pleural effusion of an
IBC patient, as described elsewhere [10].
Reagents
CEP-37440 was synthesized and provided by Teva
Branded Pharmaceutical Products R&D, West Chester,
PA, USA. CEP-37440 has modest plasma protein bind-
ing, high intrinsic solubility, reduced lipophilicity, favor-
able microsomal metabolic stability across species,
reduced capacity for drug–drug interaction, and pos-
sesses favorable oral bioavailability and a lower clearance
rate in vivo across multiple species [21]. For in vitro as-
says, CEP-37440 free base was dissolved in dimethyl
sulfoxide (DMSO) at concentration of 4 mM. For in vivo
studies, CEP-37440 tri-hydrochloride di-hydrate salt was
used and the drug was dissolved in distilled water. The
media for the different cell lines are described in
(Additional file 12).
Total FAK1 and phospho-FAK1 (Tyr 397) assays
Cells were grown to 80 % confluence in 100 mm in
diameter Petri dishes. Cells were collected in cold
phosphate-buffered saline (PBS) by scraping from cul-
ture plates, centrifuged, and washed twice with cold
PBS; proteins were extracted with 500 μl of cell extrac-
tion buffer (Invitrogen, Life Technologies, Carlsbad,
CA, USA) containing a mixture of protease inhibitors
(Protease Inhibitors Cocktail, Sigma-Aldrich, St. Louis,
MO, USA) and 1 mM phenylmethanesulfonyl fluoride
(PMSF). After extraction for 30 min on ice, the extracts
were centrifuged at 14,000 × g for 10 min at 4 °C, and the
supernatant was transferred to a fresh microcentrifuge
tube and kept at −80 °C until use. The protein concentra-
tion in the cell extracts was determined using the BCA
protein assay kit (Pierce, Rockford, IL, USA). Total FAK1
was studied in the cell protein extracts using FAK (Total)
enzyme-linked immunosorbent assay (ELISA) kits
(Invitrogen, Frederick, MD, USA); cell extracts were
diluted 1:40 in dilution buffer as was recommended by
the manufacturer; total FAK1 was expressed as ng total
FAK1/μg protein. To study phospho-FAK1, FAK
(pY397) ELISA kits (Invitrogen, Life Technologies,
Carlsbad, CA, USA) were used and cell extracts were
diluted 1:5 in dilution buffer; phospho-FAK1 (Y397)
was expressed as units of phospho-FAK1/μg protein.
Total ALK and phospho-ALK (Tyr 1604) assays
Total ALK and phospho-ALK (Tyr 1604) were studied
using PathScan Total ALK Sandwich ELISA and PathScan
Phospho-ALK (Tyr 1604) Sandwich ELISA kits, respect-
ively (Cell Signaling Technology, Inc., Danvers, MA,
USA); protein extracts from Karpas 299 cells, a human T
cell lymphoma cell line, were used as positive control.
Cell proliferation assays
For FC-IBC02, SUM190, MDA-IBC03, SUM149, MDA-
MB-231, MDA-MB-468, MCF-10A, and MCF-12A, a
total of 2000 cells were plated per well in a 96-well plate,
except for KPL4 in which 1000 cells were plated. After
the cells were plated, they were allowed to attach over-
night and then treated with CEP-37440 during several
time points (0 h, 24 h, 48 h, 72 h, 96 h, 120 h, 144 h,
168 h, and 192 h). Several CEP-37440 concentrations
were evaluated (0, 3, 10, 30,100, 300, 1000, 2000, and
3000 nM), and each concentration was tested in quadru-
plicate; as controls, cells growing in regular media (with-
out CEP-37440) and media with 0.075 % DMSO (vehicle)
were included. After CEP-37440 treatments, the living
cells were quantified using the CellTiter 96 Aqueous One
Solution Cell Proliferation Assay kit (Promega, Madison,
WI, USA) following the manufacturer’s instructions.
Briefly, the media with the CEP-37440 was removed, and
100 μl of fresh media was added to each well; 20 μl
3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-
2-(4-sulfophenyl)-2H-tetrazolium (MTS) compound was
added and the cells were incubated at 37 °C in a cell incu-
bator for 4 h. The absorbance at 490 nm and 630 nm
(reference wavelength) was measured with a 96-well
microplate reader (iMark™, Bio-Rad Laboratories Inc.,
Hercules, CA, USA).
Gene expression profiling
FC-IBC02 cells were treated with 1000 nM CEP-37440 for
48 h and RNA was isolated. Affymetrix Genechip® Human
Gene 1.0 ST array (Affymetrix Inc., Santa Clara, CA, USA)
were used for gene expression studies (Additional file 12).
Data analyses were performed using GeneSpring software
13.1 (Agilent Technologies, Inc., Santa Clara, CA, USA).
The criteria for differentially expressed genes were set at ≥
2.0-fold changes. Statistical analysis was performed to
compare two groups using t test unpaired with a p value
less than or equal to 0.05. A heat map was generated from
the differentially expressed gene list. The list of differen-
tially expressed genes was loaded into Ingenuity Pathway
Analysis (IPA) 8.0 software (http://www.ingenuity.com) to
perform biological network and functional analyses.
In vivo studies using SCID mice
Studies were approved by the Institutional Animal Care
Committee at Thomas Jefferson University. A total of 106
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cells were suspended in 100 μl PBS, mixed with 100 μl
Matrigel (BD Biosciences, Bedford, MA, USA), and
injected into the fourth left inguinal mammary fat pad
of severe combined immune-deficient (SCID) mice.
The animals were palpated daily for detection of tumor
development and, once the breast tumor xenografts
reached approximately 50–100 mm3 (approximately
20–30 days postinjection), the mice were randomly al-
located into groups. Two doses of CEP-37440 were
tested for mice harboring FC-IBC02 or SUM149 breast
tumor xenografts; the mice allocated to treatment re-
ceived either 30 mg/kg twice a day (bid) or 55 mg/kg
bid by oral gavage in a volume of 100 μl, 5 days/week
for 35–40 days. For mice harboring SUM190 breast
tumor xenografts, only the higher CEP-37440 dose
(55 mg/kg bid) was tested. The CEP-37440 doses were
chosen based on preliminary experiments in order to
achieve an optimal plasma concentration–response rela-
tionship [21]. Breast tumors were measured using a vernier
caliper, and tumor volumes were calculated using the fol-
lowing equation: V = [(L1 + L2)/2] × L1 × L2 × 0.526 where
L1 and L2 are the length and width of the tumor. After
40 days of treatment or when the primary tumor reached a
volume of approximately 1 cm3, the animals were eutha-
nized by carbon dioxide (CO2) inhalation. Breast tumors
and other organs (lungs, heart, liver, spleen, brain, ovaries,
kidneys, and lymph nodes) were removed, fixed in 10 %
neutral-buffered formalin and paraffin-embedded for histo-
logical examination (Additional file 12).
Statistical analyses
For the analyses of the cell proliferation data, the log-
transformed response measures (Abs 490 nm and Abs
630 nm) were modeled using the linear mixed effects
(LME) model adjusting for correlations between re-
peated measures over time. The fixed effects included
the ten concentrations and linear time trends. For the
analyses of in vivo tumor growth data, the log-transformed
tumor volumes were modeled using LME models adjusting
for correlations between repeated measures from the same
animal. The fixed effects included the control group and
treatment groups (30 mg/kg CEP-37440, and 55 mg/kg
CEP-37440), and linear and quadratic time trends. The
LME models included either only linear terms or both
linear and quadratic terms as appropriate for specific
time-dependent trends. Percent tumor growth inhib-
ition (% TGI) was calculated as follows: 100 × [(tumor
volume of the control group at the end of treatment −
tumor volume of the treated group at the end of the
treatment)/tumor volume of the control group at the
end of the treatment] = 100 × (1-exp (mean difference
in log volumes at the end of the treatment), where the
mean difference in log volumes at the end of the
treatment was estimated from the fitted LME models. The
data were analyzed using R package ‘nlme’ (The R Foun-
dation for Statistical Computing http://www.R-
project.org).
Results
FAK1 is phosphorylated in IBC cell lines
Using ELISA, total FAK1 and phospho-FAK1 (Tyr 397)
were studied in the IBC cell lines KPL4, MDA-IBC03,
FC-IBC02, SUM190, and SUM149, and in the non-IBC
triple-negative cell lines MDA-MB-231 and MDA-MB-
468. All of the cell lines expressed high levels of FAK1
(between 0.28 ng to 0.7 ng FAK1/μg protein), and no
differences were observed between IBC and non-IBC cell
lines (Fig. 1a). However, the levels of phospho-FAK1
(Tyr 397) differed between the cell lines (Fig. 1b). The
percentage of phosphorylated FAK1 (Tyr 397) in relation
of total FAK1 was higher in KPL4, MDA-MB-231 and
MDA-MB-468 (Fig. 1c); 4.4 % of total FAK1 was phos-
phorylated in KPL4, and approximately 3.6 % was phos-
phorylated MDA-MB-231 and MDA-MB-468. A lower
percentage of FAK1 was phosphorylated in FC-IBC02
(1.4 %), SUM149 (1.4 %), SUM190 (0.66 %), and MDA-
IBC03 (0.54 %) (Fig. 1c). We also studied the expression
of FAK1 and phospho-FAK1 in the human normal-like
breast epithelial cells MCF-10A and MCF-12A; these
cells express FAK1 (approximately 0.5 ng total FAK1/μg
protein and 0.26 ng total FAK1/μg protein, respectively)
but they did not express phospho-FAK1 (Tyr 397).
ALK was not expressed by IBC cell lines
The IBC cell lines FC-IBC02, SUM190, KPL4, SUM149
and MDA-IBC03 were tested for expression of ALK by
ELISA. The human T cell lymphoma cell line Karpas
299 that carries the NPM (nucleophosmin)-ALK fusion
gene was used as positive controls and these cells were
strongly positive for total ALK and phospho-ALK (Tyr
1604). All of the IBC cell lines tested were negative for
total ALK and phospho-ALK (Tyr 1604), and the non-
IBC cell lines MDA-MB-231 and MDA-MB-468 were
also negative for total ALK and phospho-ALK expres-
sion (data not shown).
CEP-37440 specifically decreased the proliferation of
certain IBC cells in a concentration-dependent manner
Cell proliferation rate was studied in the IBC cell lines
in the presence of several concentrations of CEP-37440.
The MTS assay that measures cellular respiration was
used as a surrogate of cell proliferation. In the presence
of 300 nM CEP-37440, FC-IBC02 significantly decreased
in proliferation compared to the control without the
drug, and 1000 nM CEP-37440 completely inhibited FC-
IBC02 proliferation, killing these cells after 72 h of treat-
ment (Fig. 2a). FC-IBC02 showed a positive linear
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growth rate when the cells were in the presence of lower
concentrations of CEP-37440 (3 nM, 10 nM, 100 nM
and 300 nM) (Additional file 1: Figure S1 and Additional
file 2: Table S1); in contrast, the growth rates in the
cells treated with high concentrations of CEP-37440
(1000 nM, 2000 nM and 3000 nM) were not signifi-
cantly different from time 0 (Additional file 1: Figure S1
and Additional file 2: Table S1).
In KPL4 cells, treatment with 1000 nM CEP-37440 for
144 h reduced significantly the proliferation of cells com-
pared to the control, and the growth rate was even lower
in the presence of 2000 nM or 3000 nM CEP-37440
(Fig. 2b). The growth rate in the KPL4 cells treated with
the 3000 nM CEP-37440 was the lowest (Additional file 3:
Figure S2 and Additional file 4: Table S2).
In SUM190 cells, treatment with 1000 nM CEP-37440
for 144 h reduced proliferation to approximately 60 %
(Fig. 2c). The response measures corresponding to all
concentrations except for 3000 nM grew over time and
were significantly different from zero rates (Additional
file 5: Figure S3 and Additional file 6: Table S3). The
IBC cell line MDA-IBC03 only responded to a very high
concentration of CEP-37440 (Fig. 2d), and SUM149
showed a slight response to high CEP-37440 concentra-
tions (Fig. 2e). We also tested the effect of CEP-37440
on the triple-negative non-IBC cell lines MDA-MB-231
and MDA-MB-468 (Fig. 3a and b). Treatment with 2000
nM CEP-37440 for 144 h reduced MDA-MB-231 and
MDA-MB-468 proliferation to approximately 46–54 %
(Fig. 3a, 3b). We also studied the potential cytotoxic
effects of CEP-37440 on normal breast epithelial cells,
MCF-10A and MCF-12A (Fig. 3c and d). We found that
300 nM or 1000 nM CEP-37440 did not affect the prolif-
eration of these cells; 2000 nM CEP-37440 decreased
their proliferation to approximately 50 % and 3000 nM
CEP-37440 inhibited their proliferation almost com-
pletely (Fig. 3c, 3d). The drug concentration required to
reduce growth rates to 50 % (GI50) for each cell line are
shown in Table 1.
In conclusion, CEP-37440 at low concentration specif-
ically reduced the proliferation of three out of five IBC
cell lines; FC-IBC02, KPL4 and SUM190 cells showed
decreased proliferation in the presence of 1000 nM CEP-
37440, and this same concentration did not significantly
reduce the proliferation of normal breast epithelial cells.
The CEP-37440 concentrations required to reduced the
growth rate to 50 % (GI50) for each cell line are indicated
in Table 1. The sensitivity of these IBC cell lines to CEP-
37440 was not related to the cell subtype since FC-IBC02
is a triple-negative cell line, and KPL4 and SUM190 are
human epidermal growth factor receptor 2; (ErbB2)-posi-
tive (Table 1). MDA-IBC03 and the triple-negative non-
IBC cell lines MDA-MB231 and MDA-MB-468 were less
sensitive to CEP-37440, and the IBC cell line SUM149 was
slightly affected by the drug.
CEP-37440 decreases phospho-FAK1 (Tyr 397) and maintains
its low level over time in FC-IBC02, SUM 190, and KPL4
To test the effect of CEP-37440 on the autophosphoryl-
ation of FAK1 and its Tyr 397 site, IBC cell lines were
treated with 1000 nM CEP-37440 during different time
intervals (0 h, 48 h, 72 h, 96 h, and 120 h) and total
FAK1 and phospho-FAK1 (Tyr 397) were studied (Fig. 4).
In FC-IBC02 cells treated with CEP-37440, the levels of
total FAK1 were similar compared to the control with-
out treatment (0.5 ng to 0.6 ng total FAK1/μg protein)
(Fig. 4a), but the levels of phospho-FAK1 decreased over
Fig. 1 Total and phosphorylated FAK1 in IBC and non-IBC cell lines.
a Total FAK1; b phospho-FAK1 (Tyr 397); c percentage of phospho-
FAK1 compared to total FAK1 in different cell lines ([phospho-FAK1/
total FAK1] × 100). Standard errors (SE) are indicated in each case.
FAK1 focal adhesion kinase 1, IBC inflammatory breast cancer
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time in the cells treated with CEP-37440, reaching a
value lower than 0.002 units phospho-FAK1/μg protein
at 72 to 120 h of treatment (Fig. 4b). In SUM190 cells,
the levels of total FAK1 decreased to approximately
50 % in the cells treated with 1000 nM of CEP-37440
compared to the control without treatment (Fig. 4a),
and the phospho-FAK1 (Tyr 397) decreased from 0.07
units/μg protein in the control to 0.0015 units/μg
protein in the CEP-37440-treated cells after 48 to
120 h of treatment (Fig. 4b). In both FC-IBC02 and
SUM190 cells, the levels of phospho-FAK1 (Tyr 397)
reached similar levels (0.0015 to 0.002 units/μg pro-
tein) after the treatment with 1000 nM CEP-37440 for
48 h (Fig. 4b).
In KPL4 cells, the levels of total FAK1 were similar
between cells treated with CEP-37440 and the control
Fig. 2 Effect of CEP-37440 on IBC cell lines proliferation. Several concentrations of CEP-37440 were tested on the IBC cell lines: a FC-IBC02, b
KPL4, c SUM190, d MDA-IBC03, and e SUM149. CEP-37440 at low concentration (1000 nM) inhibited the proliferation of the IBC cells FC-IBC02,
KPL4 and SUM190 but did not affect MDA-IBC03 and SUM149 proliferation. At higher concentration, 3000 nM CEP-37440, inhibited MDA-IBC03
proliferation. CEP-37440 did not inhibit SUM149 proliferation. Each point in the graphic represents the mean ± standard errors (SE) of four
replicates. IBC inflammatory breast cancer
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without treatment (Fig. 4a), however, there was a signifi-
cant decrease in phospho-FAK1 (Tyr 397) after CEP-37440
treatment from 2.5 % in the control without treatment to
1.4 % in cells treated with CEP-37440 (Fig. 4b and 4c). In
SUM149, the levels of total FAK1 in treated cells were
similar to the control during the first 72 h of treatment,
decreasing from 0.4–0.2 ng total FAK1/μg protein after
96–120 h of CEP-37440 treatment (Fig. 4a); however there
was a slightly decrease of phospho-FAK1, decreasing from
0.019 Units phospho-FAK1/ μg protein in the control to
0.008-0.009 Units phospho-FAK1/ μg protein at 96-120 h
of CEP-37440 treatment (Fig. 4b). In SUM149, there was a
decrease from 4.9 % phospho-FAK1 in the control without
treatment to 3.8 % phospho-FAK1 after 120 h of CEP-
37440 treatment (Fig. 4c).
In conclusion, low concentration of CEP-37440
(1000 nM) was able to decreased phospho-FAK1 by
half in FC-IBC02, SUM190, and KPL4 cells after 48 h
of treatment compared to the controls without treat-
ment, while in SUM149, it only decreased slightly.
Expression arrays analyses of FC-IBC02 cells treated with
CEP-37440
FC-IBC02 IBC cells were selected for expression array
analyses because our previous results showed that CEP-
37440 at low concentration (1000 nM) was able to
completely inhibit the proliferation of these cells in vitro.
Cells were treated with 1000 nM CEP-37440 for 48 h,
RNA was isolated from the cells, and expression studies
were performed. The microarray data have been deposited
into the NCBI’s gene expression omnibus (GEO) data sets
(GSE73285). A total of 43 genes showed changes in their
expression when cells were treated with CEP-37440 com-
pared to the control (2.0-fold, p = 0.05), with ten downreg-
ulated and 33 upregulated genes (Fig. 5 and Table 2).
Using IPA, the major functions affected by CEP-37440
were cell death and survival, cellular growth and prolifera-
tion, and motility. Among key upregulated genes, those
related to interferon signaling and cytokines were upregu-
lated as follows: IFI27 (4.3-fold), IFI6 (3.5-fold), IFI35 (2.4-
fold), IRF7 (2.1-fold), CCL5 (4.6-fold), IL32 (3.6-fold), and
IL23A (2.1-fold). Similarly, the expression of interferon-
stimulated genes was upregulated, as well: OAS2 (5.8-
fold), OAS3 (3.5-fold), OAS1 (3.3-fold), MX1 (2.6-fold),
and ISG15 (2.4-fold). CEP-37440 upregulated two other
genes related to cell death and survival: BIK (2.3-fold) and
KDR (2.3-fold).
CEP-37440 inhibited breast tumor growth in the IBC
breast tumor xenograft models
CEP-37440 was tested in vivo using the triple-negative
FC-IBC02 and SUM149 and the ErbB2-positive SUM190
Fig. 3 Effect of CEP-37440 on the proliferation of non-IBC breast tumor cells and normal breast epithelial cells. Several concentrations of CEP-
37440 were tested on the cell lines: a MDA-MB-231, b MDA-MB-468, c MCF-10A and d MCF-12A. CEP-37440 at high concentration inhibited the
proliferation of the triple-negative non-IBC cell lines MDA-MB-231 and MDA-MB-468 but, also decreased the proliferation of normal breast epithe-
lial cells. A concentration of 3000 nM CEP-37440 inhibited MDA-MB-231 and MDA-MB-468 proliferation but also inhibited the proliferation of the
normal-like breast epithelial cells MCF-10A and MCF-12A. Each point in the graphic represents the mean ± standard errors (SE) of four replicates. IBC in-
flammatory breast cancer
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IBC breast xenograft models. The IBC cells were
injected in the mammary fat pad of female SCID mice,
and treatment with CEP-37440 began once the breast
tumor xenografts reached approximately 50–100 mm3.
All of the mice injected with FC-IBC02 or SUM149 de-
veloped breast tumor xenografts, and two doses of CEP-
37440 (30 mg/kg and 55 mg/kg) were tested in these
mice. In the animals harboring FC-IBC02 breast tumor
xenografts, mice treated with 55 mg/kg bid CEP-37440
showed smaller tumor breast xenografts compared to
the control group that did not receive the drug (Fig. 6).
The breast tumor growth was significantly lower in the
Fig. 4 Total FAK1 and phospho-FAK1 in cells treated with 1000 nM
CEP-37440 during time. a Total FAK1; b phospho- FAK1; c percent-
age of phospho-FAK1 ([phospho-FAK1/ total FAK1] x 100). Total and
phospho-FAK1 (Tyr 397) were studied in the IBC cell lines FC-IBC02,
KPL4, SUM190, and SUM149 treated with 1000 nM CEP-37440 during
different time points. Control, cells grow in media without CEP-
37440. Standard errors (SE) are indicated. FAK1 focal adhesion kinase
1, IBC inflammatory breast cancer
Fig. 5 Heat map of FC-IBC02 cells treated with CEP-37440. FC-IBC02
cells were treated with 1000 nM CEP-37440 for 48 h, RNA was isolated
and expression arrays were performed. RNA isolate from FC-IBC02
without treatment was used as control. Red, yellow and blue colors
indicate levels above, at, and below mean expression, respectively.
In the color scale, fold induction values are indicated
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Table 2 Genes dysregulated in FC-IBC02 cells by CEP-37440
Gene symbol Gene description Fold induction p value
IFI27 Interferon, alpha-inducible protein 27 4.3 0.002
IFI6 Interferon, alpha-inducible protein 6 3.5 0.003
IFI35 Interferon-induced protein 35 2.4 0.013
IRF7 Interferon regulatory factor 7 2.1 0.036
CCL5 Chemokine ligand 5 (Rantes) 4.6 0.008
IL32 Interleukin 32 3.6 0.044
IL23A Interleukin 23, alpha subunit P19 2.1 0.028
OAS2 2'-5'-oligoadenylate synthetase 2, 69/71 kDa 5.8 0.016
OAS3 2'-5'-oligoadenylate synthetase 3, 100 kDa 3.5 0.022
OAS1 2'-5'-oligoadenylate synthetase 1, 40/46 kDa 3.3 4.70E-04
MX1 MX dynamin-like GTPase 1 2.6 0.005
ISG15 ISG15 ubiquitin-like modifier 2.4 0.021
BIK BCL2-interacting killer (apoptosis-inducing) 2.3 0.016
KDR Kinase insert domain receptor 2.3 0.012
LAMP3 Lysosomal-associated membrane protein 3 3.6 0.013
CMPK2 Cytidine monophosphate kinase 2 3.0 0.03
KLHL38 Kelch-like family member 38 2.8 0.009
EFR3B EFR3 homolog B 2.8 3.14E-04
KRT75 Keratin 75, type II 2.8 0.013
GNG11 Guanine nucleotide-binding protein, gamma 11 2.6 0.010
PLAUR Plasminogen activator, urokinase receptor 2.6 0.024
HLA-B Major histocompatibility complex, class I, B 2.4 2.50E-04
NPAS2 Neuronal PAS domain protein 2 2.4 0.031
HLA-B|HLA-C Major histocompatibility complex, 2.3 2.38E-04
TAP1 Transporter 1, ATP-binding cassette, sub-family B 2.3 0.048
USP18|USP41 Ubiquitin specific peptidase 18/41 2.3 0.013
FNDC1 Fibronectin type III domain-containing 1 2.2 0.033
CD74 CD74 molecule 2.2 0.03
PSMB9 Proteasome subunit, beta type, 9 2.2 0.013
BHLHE41 Basic helix-loop-helix family, member E41 2.1 0.018
DLX2 Distal-less homeobox 2 2.1 0.025
DUSP5P Dual specificity phosphatase 5 pseudogene 1 2.0 0.007
HLA-J|HLA-A Major histocompatibility complex 2.0 0.007
OR2M1P|OR2M7 Olfactory receptors −3.5 0.023
FMO2 Flavin containing monooxygenase 2 −2.6 0.026
RGS5 Regulator of G protein signaling 5 −2.6 0.036
TF Transferrin −2.2 0.031
CABP7 Calcium-binding protein 7 −2.2 0.021
LZTFL1 Leucine zipper transcription factor-like 1 −2.2 0.044
ATCAY Ataxia, cerebellar, Cayman type −2.1 0.038
EYA4 EYA transcriptional coactivator and phosphatase 4 −2.1 0.023
SMYD1 SET and MYND domain-containing 1 −2.0 0.041
TNMD Tenomodulin −2.0 0.007
Cells were treated with 1000 nM CEP-37440 during 48 h and expression studies were performed
Salem et al. Breast Cancer Research  (2016) 18:37 Page 9 of 15
group treated with 55 mg/kg bid CEP-37440 than the
control group without treatment over the 7-week study
(p ≤ 0.001) (Additional file 7: Figure S4 and Additional
file 8: Table S4). Also, mice treated with 55 mg/kg bid
showed smaller tumors than the mice treated with
30 mg/kg bid CEP-37440 over the entire duration of the
study (Additional file 7: Figure S4). At the end of the
study, there was approximately 33 % reduction in the
FC-IBC02 breast tumor xenograft size after the mice
were treated with 55 mg/kg bid CEP-37440 (week 8;
40 days of treatment) (Fig. 6a) (p = 0.128). Furthermore,
there was approximately 21 % reduction in the FC-IBC02
breast tumor xenografts size after the mice were treated
with 30 mg/kg bid CEP-37440 at week 8 (40 days of
treatment) (p = 0.380) (Fig. 6a). FC-IBC02 mice treated
with CEP-37440 showed no signs of toxicity, such as hair
loss or significant weight loss compared to the control
group without treatment (Fig. 6b). Importantly, although
our previous experiments showed that 20 % of the mice
with FC-IBC02 breast xenografts developed spontaneous
metastatic brain tumors (Fig. 7c), none of the mice treated
with CEP-37440 (30 mg/kg or 55 mg/kg) developed brain
tumors. No differences in the number of metastatic sites
in the lungs were found when comparing the 55 mg/
kg CEP-37440-treated mice (Fig. 7e) and the control
group (Fig. 7b) .
In animals harboring SUM149 breast tumor xeno-
grafts, mice treated with CEP-37440 showed smaller
tumor breast xenografts compared to the control group
that did not receive the drug (Fig. 8a). The breast tumor
growth was significantly lower in the mice treated with
CEP-37440 than in the control group without treatment
over the 7-week study, although the growth of the tu-
mors was lower in the mice treated with 30 mg/kg bid
than with 55 mg/kg bid CEP-37440 (Additional file 9:
Figure S5 and Additional file 10: Table S5). At the end
of the study (week 7, 35 days of treatment), there was
approximately 43 % reduction in the SUM149 breast
tumor xenograft size after the mice were treated with
30 mg/kg bid CEP-37440 (p = 0.021) and approximately
23 % reduction in the SUM149 breast tumor xenografts
size after the mice were treated with 55 mg/kg bid CEP-
37440 at week 7 (p = 0.302). SUM149 breast tumor
xenograft mice treated with CEP-37440 showed no sig-
nificant weight loss compared to the control group that
was not treated with CEP-37440 (Fig. 8b).
CEP-37440 was also tested in mice harboring
SUM190 ErbB2-positive breast tumor xenografts. A
significant difference in the size of the SUM190
breast tumor xenografts was observed in the treated
group when compared to mice in the control group
that did not receive the drug (Fig. 9a). There was
79.7 % reduction in the SUM190 breast tumor xeno-
graft size after the mice were treated with 55 mg/kg bid
CEP-37440 for 35 days (week 7) (p = 0.001) (Additional
file 11: Table S6). There were no significant differences
between the weight of the control and CEP-37440-treated
mice (Fig. 9b).
Discussion
Our studies showed that low concentrations of CEP-
37440 specifically decreased the proliferation of the IBC
cell lines FC-IBC02, SUM190, and KPL4 without affect-
ing proliferation of normal breast epithelial cells. These
IBC cells were sensitive to low concentrations of CEP-
37440 and their sensitivity was independent of the cell
subtype (triple-negative or ErbB2-positive). At higher
concentrations, CEP-37440 also inhibited the prolifera-
tion of the IBC cell line MDA-IBC03 and the triple-
negative non-IBC cell lines MDA-MB-231 and MDA-
Fig. 6 In vivo studies: effect of CEP-37440 on mice with FC-IBC02
breast tumor xenografts. Mice were injected with 106 FC-IBC02 cells
in the mammary fat pad; when the breast tumor xenografts reached
approximately 50 mm3, treatments with CEP-37440 began. Treatments
with CEP-37440 were performed twice a day during 8 weeks. a Volumes
of breast tumor xenografts in the control group (without treatment) or
mice treated with 30 mg/kg or 55 mg/kg CEP-37440; b weights of the
mice in the different groups. Standard deviations (StDEV) are indicated
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MB-468. Since CEP-37440 is a dual inhibitor of FAK1
and ALK, we studied the expression of both proteins in
the IBC cell lines and found that they expressed FAK1
but not ALK. We demonstrated that CEP-37440 de-
creased the cell proliferation of FC-IBC02, SUM190, and
KPL4 by blocking the autophosphorylation kinase activ-
ity of FAK1 (Tyr 397).
We previously showed that IBC cells exhibit amplifica-
tion of the chromosomal arm 8q where FAK1 is located
(8q24.3) [10]. However, gene expression studies using ar-
rays did not show any correlation between copy number
and RNA expression in these IBC cell lines [10]. Fur-
thermore, our present work did not find a correlation
between elevated total FAK1 expression at the protein
level and FAK1 gene amplification in either IBC cells or
triple-negative non-IBC cell lines. Increased dosage of
the FAK1 gene is invariantly observed in the cell lines
derived from human cancers of lung, breast, colon, and
invasive squamous cell carcinomas [22]. However, ele-
vated FAK1 protein expression is not always correlated
with amplification of the FAK1 gene. In human head
and neck squamous cell carcinoma, not all cases with an
amplification of the FAK1 gene display FAK1 protein
overexpression, implicating a sophisticated posttran-
scriptional regulation involved in FAK1 expression and
function [23].
In vivo studies showed that CEP-37440 significantly
decreased breast tumor growth in the SUM190 and
FC-IBC02 mouse xenograft models, and the tumor
growth inhibition was dose and time dependent. Mice
harboring SUM190 and FC-IBC02 breast tumor xeno-
grafts showed 79.7 % and 33 % TGI, respectively,
when treated with 55 mg/kg bid CEP-37440 for 35–
40 days. The tumor breast xenografts of mice treated
with CEP-37440 showed lower levels of phospho-
FAK1 (Tyr 397) than the breast tumor xenografts in
the control groups (data not shown). Although the
IBC cell line SUM149 showed in vitro only a slight
response to high concentrations of the drug, CEP-
37440 reduced the size of the primary tumor in the
mice harboring SUM149 breast tumor xenografts, and
results were better with 30 mg/kg bid than 55 mg/kg
bid CEP-37440. Since there was no total regression of
the primary tumor or metastatic sites in the lungs in
mice harboring IBC xenografts, our results suggest
that a combination therapy approach would be more
effective for IBC patients than CEP-37440 alone. Pre-
clinical studies showed that the combination therapy
approach using inhibitors of FAK1 with other signal-
ing pathways increased the efficacy of single inhibitors
[22, 23]. These types of combinatorial studies have
not been conducted with CEP-37440 in preclinical models
of IBC or triple-negative breast cancer (TNBC).
None of the FC-IBC02 breast xenograft mice treated
with CEP-37440 developed brain metastases in contrast
to 20 % in the control group. This data suggests that
CEP-37440 is able to cross the blood-brain barrier. Re-
lated work by another group found that TAE226,
another small molecule inhibitor targeting the ATP-
binding site of FAK1, increased apoptosis of glioblast-
oma, an infiltrative brain tumor, and inhibited tumor
growth [24].
The overexpression and phosphorylation of FAK1 on
Tyr 397 is frequently associated with tumor metastasis
as well as poor patient prognosis [25–28], indicating a
critical role for activated FAK1 in tumor progression
and malignancy. Tyrosine 397 is the main autophospho-
rylation site of FAK1, leading to activation of its intrinsic
Fig. 7 Histological specimens in mice harboring FC-IBC02 breast tumor xenograft. Specimens from the control group (without treatment): a breast
tumor xenograft, b lung metastases, and c brain metastasis. Specimens from mice treated with 55 mg/kg CEP-37440: d breast tumor xenograft, and
e lung metastases. Multiple metastatic sites were observed in the lungs of the control and treated mice. A single focus of metastatic tumor cells in the
brain was found in two mice from the control group; no brain metastases were found in the mice treated with CEP-37440. Hematoxilin and eosin
(H&E) stain. Magnification: ×40
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kinase function as well as its downstream signaling
players, and providing a high-affinity binding site for the
SH2 domain of Src family kinases [29, 30]. Furthermore,
phospho-FAK1 binds to the p85 subunit of phos-
phatidylinositol 3-kinase (PI3K) at the Tyr 397
autophosphorylation site. Phospholipid production stim-
ulated by phospho-FAK1 and activation of PIK3 can
stimulate AKT kinase, which inhibits apoptosis by regu-
lating various cell death cascade proteins [31]. In
addition to its roles as a cytoplasmic kinase, recent stud-
ies revealed that FAK1 can translocate to the nucleus
where it can influence the expression of chemokines,
which are secreted to the surrounding environment [32].
These proteins recruit regulatory T cells (Treg) into tu-
mors, which in turn suppress the CD8 antitumor re-
sponse. Therefore, nuclear FAK1 signaling in cancer
cells can help establish an environment within the tumor
that supports survival and growth. FAK1 kinase inhib-
itors target mechanisms of immune suppression and
may therefore represent a form of effective “immune-
modulatory” therapy that reduces regulatory T cells in
the tumor environment [32]. We showed that CEP-
37440 treatment of the IBC cell line FC-IBC02 in-
creased the expression of multiple genes related to
interferon signaling and cytokines.
In a recent study, FAK1 expression was analyzed in
breast primary tumor samples from stages III–IV pa-
tients and a significant association between high
FAK1 expression in the primary tumor, lymphovascu-
lar invasion, and triple-negative phenotype was found.
In addition, a strong positive correlation was observed
between high FAK1 expression and shorter overall
Fig. 9 In vivo studies: effect of CEP-37440 on mice with SUM190
breast tumor xenografts. Mice were injected with 106 SUM190 cells
in the mammary fat pad; when the breast tumor xenografts reached
approximately 100 mm3, treatment with 55 mg/kg bid CEP-37440
began. Treatments with CEP-37440 were performed twice a day during
7 weeks (35 days of treatment). a Volumes of breast tumor xenografts in
the control group (without treatment) or mice treated with 55 mg/kg
CEP-37440; b weights of the mice in the different groups. Standard
errors (SE) are indicated
Fig. 8 In vivo studies: effect of CEP-37440 on mice with SUM149
breast tumor xenografts. Mice were injected with 106 SUM149 cells
in the mammary fat pad; when the breast tumor xenografts reached
approximately 50 mm3, treatments with CEP-37440 began. Treatments
with CEP-37440 were performed twice a day during 7 weeks (35 days of
treatment). a Volumes of breast tumor xenografts in the control group
(without treatment) or mice treated with 30 mg/kg or 55 mg/kg
CEP-37440; b weights of the mice in the different groups. Standard
deviations (StDEV) are indicated
Salem et al. Breast Cancer Research  (2016) 18:37 Page 12 of 15
survival and progression-free survival in patients with
metastatic tumors [33]; however, it was not specified
by the authors if IBC samples were included in the
study. The role of ALK in IBC is controversial, with
some studies showing amplification of ALK in IBC
and in others showing no amplification [34, 35], and
the present work showed that none of the IBC cell
lines expressed the ALK protein.
FAK1 is one of the most attractive tyrosine kinase tar-
gets in cancer therapy since it plays a role in signal trans-
duction and in the development of numerous human
tumors, including breast, colon, thyroid, prostate, pan-
creas, and brain cancers [36]. Besides CEP-37440, several
other small molecule inhibitors of FAK1 that target the
ATP-binding site and block FAK1 kinase activity have
been developed. One of these inhibitors, PF-562,271 from
Pfizer decreased tumor growth in multiple xenograft
models [37, 38], and was shown to be effective in phase I
trials [39]; however, it showed nonlinear pharmacokinetics
and was henceforth discontinued. VS-6063 (defactinib)
from Verastem showed more favorable pharmacokinetics,
and in a phase I trial it demonstrated a favorable response
in some patients with ovarian, colorectal, or bile duct
cancer. Other FAK1 inhibitors, including VS-4718 (or
PND-1186) [40], VS-5095, and GSK2256098, are in early
clinical trials.
Finally, our in vivo experiments demonstrated that
animals treated with CEP-37440 did not experience re-
duced body weight or hair loss, suggesting that CEP-
37440 was not toxic for mice at a dose of 30 or
55 mg/kg/bid. CEP-37440 is currently in a phase I
dose-escalation clinical trial in patients with solid tumors
(www.clinicaltrials.gov NCT01922752). Based upon the
preclinical studies described above and the data available
for other FAK1 inhibitors, CEP-37440 may have clinical
applications as part of a combinatorial therapy against
IBC.
Conclusions
These results suggest that CEP-37440 could be effective
against IBC cells that express phospho-FAK1 (Tyr 397)
if the drug is able to decrease the level of phospho-FAK
(Tyr-397). Our results also suggest that combinational
therapies could be more effective than using CEP-37440
as a single agent.
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